Multiple Myeloma News
Phase 3 Trial of Ciltacabtagene Autoleucel Meets Primary Endpoint in Relapsed, Refractory Multiple Myeloma
Source: OncLive articles The trial is the first randomized phase 3 study evaluating the efficacy and safety of ciltacabtagene autoleucel patients with relapsed and lenalidomide-refractory multiple myeloma. Read More
GPRC5D as a novel immunotherapeutic target in multiple myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
Efficacy and Safety of Ide-Cel Confirmed in Real-World Multiple Myeloma Population
Source: Myeloma - Hematology Advisor Researchers sought to confirm the safety and efficacy of idecabtagene vicleucel in a real-world population of patients with relapsed/refractory multiple myeloma. Read More
Unmet Needs in Treatment of Multiple Myeloma
Source: OncLive articles Kathryn Maples, PharmD, BCOP, provides insights regarding unmet needs in treatment for relapsed/refractory multiple myeloma. Read More
Treatment Landscape Surrounding Multiple Myeloma
Source: OncLive articles A panel of experts navigate the treatment landscape in multiple myeloma. Read More
Triplet Maintenance Extends PFS After Transplant in Multiple Myeloma
Source: Myeloma - Hematology Advisor Phase 3 trial results support the use of carfilzomib, lenalidomide, and dexamethasone as maintenance after autologous stem cell transplant in patients with multiple myeloma. Read More
Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myeloma
Source: Myeloma : nature.com subject feeds Post Content Read More
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results
Source: Myeloma : nature.com subject feeds Post Content Read More
Safety and efficacy of autologous stem cell transplantation in dialysis-dependent myeloma patients—The DIADEM study from the chronic malignancies working party of the EBMT
Source: Myeloma : nature.com subject feeds Post Content Read More
Multiple Myeloma Therapy Often Causes Cardiovascular Complications
Source: OncLive articles Many patients have baseline risk factors present at diagnosis because of older age and disease-related elements. Read More